Financial Data and Key Metrics Changes - For Q1 2025, revenue from sales of MPEFA was reported at $1.1 million, compared to $1.1 million for Q1 2024 [25] - Research and development expenses increased to $15.3 million from $14.4 million year-over-year, reflecting expenses associated with late-stage development programs [25] - Selling, general, and administrative expenses decreased significantly to $11.6 million from $32.1 million, primarily due to strategic repositioning efforts [25] - The net loss for Q1 2025 was $25.3 million or $0.07 per share, compared to a net loss of $48.4 million or $0.20 per share for the same period in 2024 [25] - Cash and short-term investments at the end of Q1 2025 were $194.8 million, down from $238 million at the end of 2024 [26] Business Line Data and Key Metrics Changes - The company announced an exclusive license agreement with Novo Nordisk for LX9851, which includes potential milestone payments of up to $1 billion and tiered royalties on future net sales [5][6] - The Phase 2b study of pilavapitan showed a well-tolerated dose with clear evidence of effect, paving the way for Phase 3 studies [7][9] - Enrollment in the global pivotal Sonata HCM study of sotagliflozin is on track, with expectations for all Phase III sites to be operational by Q3 2025 [13][18] Market Data and Key Metrics Changes - Approximately 9 million people in the U.S. are currently affected by diabetic peripheral neuropathic pain (DPNP), with projections to grow to 13 million by 2035 [10] - In the U.S., there are over 1 million people with hypertrophic cardiomyopathy (HCM), with a significant portion having non-obstructive HCM [14] Company Strategy and Development Direction - The company is focused on advancing its R&D programs and has restructured its cost base to support this pivot [7][8] - The partnership with Novo Nordisk is seen as a validation of the science behind LX9851 and aims to maximize its market potential [6][20] - The company is committed to advancing pilavapitan for DPNP and sotagliflozin for HCM, with plans for further regulatory engagement and data presentations [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of pilavapitan to be the first novel oral non-opioid DPNP medication in over two decades, highlighting the significant unmet need in this market [9][11] - The company anticipates stable U.S. MPEFA revenues despite limited promotional activity and expects lower cash usage in subsequent quarters [26][27] - Management is optimistic about the upcoming catalysts and the potential for new partnerships to enhance the value of its pipeline [28][30] Other Important Information - The company has revised its operating expense guidance for 2025, expecting total operating expenses between $135 million and $145 million [27] - The partnership with Beatrice for sotagliflozin includes a $25 million upfront payment and potential milestone payments of up to $200 million [21] Q&A Session Summary Question: Can you discuss the intended trial designs for the pain program? - The plan is to run two parallel trials with similar designs, one U.S.-only and the other worldwide, with approximately 300-350 patients per arm [34] Question: How are the IND enabling studies for LX9851 progressing? - The IND enabling studies are on track for completion this year, with a strong collaborative relationship with Novo Nordisk [43] Question: Is the end of Phase II meeting a gating factor for strategic discussions? - It is not seen as a gating factor; discussions with strategic partners will continue concurrently [52] Question: What additional data will be presented at medical meetings? - Additional detail on secondary analyses related to pain quality and functionality will be shared, along with pharmacokinetic data [55] Question: How is the Sonata trial designed to create a homogeneous population? - The trial focuses on symptomatic disease, which is reflective of diastolic dysfunction, and is powered for both obstructive and non-obstructive HCM [59][66]

Financial Data and Key Metrics Changes - For Q1 2025, revenue from sales of MPEFA was reported at $1.1 million, compared to $1.1 million for Q1 2024 [25] - Research and development expenses increased to $15.3 million from $14.4 million year-over-year, reflecting costs associated with late-stage development programs [26] - Selling, general, and administrative expenses decreased significantly to $11.6 million from $32.1 million, primarily due to strategic repositioning efforts [26] - The net loss for Q1 2025 was $25.3 million, or $0.07 per share, compared to a net loss of $48.4 million, or $0.20 per share, for the same period in 2024 [26] - Cash and short-term investments at the end of Q1 2025 were $194.8 million, down from $238 million at the end of 2024 [27] Business Line Data and Key Metrics Changes - The company announced an exclusive license agreement with Novo Nordisk for LX9851, which includes potential milestone payments of up to $1 billion and tiered royalties on future net sales [6][20] - The Phase 2b study of pilavapitan showed a well-tolerated dose with clear evidence of effect, paving the way for Phase 3 studies [7][10] - Enrollment in the global pivotal Sonata HCM study of sotagliflozin is on track, with expectations for all Phase III sites to be operational by Q3 2025 [19][31] Market Data and Key Metrics Changes - Approximately 9 million people in the U.S. are currently affected by diabetic peripheral neuropathic pain (DPNP), with projections to rise to 13 million by 2035 [11] - In the U.S., there are over 1 million people with hypertrophic cardiomyopathy (HCM), with a significant portion having non-obstructive HCM [14] Company Strategy and Development Direction - The company is focused on advancing its R&D programs and has restructured its cost base to support this pivot [8] - The partnership with Novo Nordisk is seen as a validation of the science behind LX9851 and aims to maximize its market potential [5][20] - The company is committed to developing pilavapitan as a novel oral treatment for DPNP, addressing a significant unmet need in the market [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of pilavapitan to be the first novel oral non-opioid DPNP medication in over two decades, highlighting the need for new treatment options [10][12] - The company anticipates sharing full data from the PROGRESS study in Q3 and is preparing for an end-of-Phase II meeting with the FDA [30][31] - Management emphasized the importance of focusing on areas with significant unmet needs and leveraging partnerships to enhance the value of their assets [29] Other Important Information - The company expects stable U.S. MPEFA revenues despite limited promotional activity and has reiterated its operating expense guidance for 2025 [27][28] - The company is actively engaging in discussions with potential partners for pilavapitan to unlock its global value across multiple indications [23] Q&A Session Summary Question: Can you discuss the intended trial designs for the pain program? - The plan is to run two parallel trials with similar designs, one U.S.-only and the other worldwide, with approximately 300-350 patients per arm [36] Question: How are the IND enabling studies for LX9851 progressing? - The IND enabling studies are on track for completion this year, with strong collaboration with Novo Nordisk [44] Question: Will the end of Phase II meeting be a gating factor for strategic discussions? - It is not seen as a gating factor; discussions will continue concurrently [52] Question: What additional data will be presented at medical meetings? - Additional detail on secondary analyses related to pain quality and functionality will be shared [55] Question: How is the Sonata trial designed to create a homogeneous population? - The trial focuses on symptomatic disease, which is reflective of diastolic dysfunction, and is powered to see effects in both obstructive and non-obstructive HCM [60][62]

Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET LX9851 f ...

Core Insights - Lexicon Pharmaceuticals has made significant progress in 2025, focusing on R&D and achieving key milestones, including an exclusive licensing agreement with Novo Nordisk for LX9851 and positive results from the Phase 2b PROGRESS study for pilavapadin [1][3][4] Financial Performance - Revenues for Q1 2025 increased to $1.3 million from $1.1 million in Q1 2024, primarily driven by product sales of INPEFA® (sotagliflozin) [9] - Research and development expenses rose to $15.3 million in Q1 2025 from $14.4 million in Q1 2024, reflecting ongoing investments in clinical trials [10] - Selling, general and administrative expenses decreased significantly to $11.6 million in Q1 2025 from $32.1 million in Q1 2024 due to strategic repositioning and reduced marketing efforts [11] - The net loss for Q1 2025 was $25.3 million, or $0.07 per share, compared to a net loss of $48.4 million, or $0.20 per share, in Q1 2024 [12] Pipeline Developments - Pilavapadin (LX9211) is advancing towards Phase 3 development for diabetic peripheral neuropathic pain (DPNP), with the 10 mg dose showing meaningful pain reduction in the Phase 2b PROGRESS study [7][4] - LX9851, a novel oral candidate for obesity, is in preclinical development, with Lexicon eligible for up to $1 billion in milestone payments from Novo Nordisk [7][3] - The SONATA-HCM study for sotagliflozin in hypertrophic cardiomyopathy (HCM) is underway, targeting 500 patient enrollments [6][7] Cash Position - As of March 31, 2025, Lexicon had $194.8 million in cash and investments, down from $238.0 million at the end of 2024, partly due to severance payments related to strategic changes [13][20]

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/. About Lexicon Pharmaceu ...

Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000™ program, ...

Shares of Lexicon Pharmaceuticals (LXRX) have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk (NVO) last week.Per the deal terms, Lexicon will complete certain preclinical activities before Novo Nordisk takes over the development, manufacturing and commercialization of LX9851. NVO will also be responsible for LX9851’s investigational new drug (IND) filing.In return, LXRX is eligible to receive $75 million as an upfront payment from NVO. Inclu ...

Group 1 - Lexicon Pharmaceuticals will participate in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, at 8:00 a.m. ET [1] - The presentation will be accessible live and via replay on the company's website [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The Genome5000™ program has enabled Lexicon to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [2] - The company has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]

Core Viewpoint - Lexicon Pharmaceuticals has entered into an exclusive license agreement with Novo Nordisk for LX9851, a novel oral treatment for obesity and metabolic disorders, enhancing both companies' positions in the market [1][4]. Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, with a unique genomics target discovery platform that has identified over 100 protein targets with therapeutic potential [6]. - Novo Nordisk is a leading global healthcare company specializing in diabetes care and obesity management, committed to scientific breakthroughs and expanding access to medicines [7]. Agreement Details - Under the agreement, Novo Nordisk gains exclusive worldwide rights to develop, manufacture, and commercialize LX9851, while Lexicon will handle the completion of Investigational New Drug (IND) application-enabling activities [1]. - Lexicon is eligible for upfront and near-term milestone payments totaling up to $75 million, with potential total payments reaching $1 billion, including tiered royalties on net sales of LX9851 [2]. Product Information - LX9851 is a potent oral small molecule inhibitor of Acyl-CoA Synthetase 5 (ACSL5), which is crucial in regulating fat accumulation and energy balance [3]. - Preclinical data indicates that LX9851, when combined with semaglutide, significantly reduces weight, food intake, and fat mass, and also mitigates weight regain and improves liver steatosis after semaglutide discontinuation [3][5]. Strategic Importance - The partnership with Novo Nordisk strengthens Lexicon's financial position and provides opportunities for further investment in its R&D portfolio [4].

Drug Development and Clinical Trials - The company is commercializing INPEFA (sotagliflozin) to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors[31]. - The FDA issued a complete response letter in December 2024 regarding the company's NDA for ZYNQUISTA (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and CKD, with ongoing proceedings for a public Notice of Opportunity for Hearing[35]. - The company is conducting a Phase 3 clinical trial, SONATA HCM, to evaluate the efficacy and safety of sotagliflozin in approximately 500 patients with hypertrophic cardiomyopathy (HCM) over a 26-week treatment period[33]. - Pilavapadin (LX9211) has received Fast Track designation from the FDA for the treatment of diabetic peripheral neuropathic pain (DPNP), with three completed Phase 2 clinical trials demonstrating evidence of effect[18][21]. - In the PROGRESS Phase 2b clinical trial, the 10 mg dose of pilavapadin achieved a reduction in average daily pain score (ADPS) of 1.74 compared to 1.31 in the placebo arm, although the study did not reach statistical significance on the primary endpoint[23]. - The RELIEF-DPN-1 Phase 2 clinical trial showed a statistically significant reduction in ADPS of 1.39 points in the low dose arm compared to 0.72 in the placebo arm (p=0.007), meeting the study's primary endpoint[24]. - The company is developing LX9851 for obesity and associated cardiometabolic disorders, with IND-enabling studies currently underway[28]. - The company is developing pilavapadin for neuropathic pain, LX9851 for obesity and cardiometabolic disorders, and sotagliflozin for HCM, with ongoing research and development efforts[118]. - Clinical trials are inherently risky and may not demonstrate safety and efficacy, potentially delaying regulatory approval[119]. Financial Performance and Capital Requirements - The company has a history of net losses and expects to continue incurring net losses, which may affect profitability[116]. - The company incurred an aggregate net loss of approximately $479.5 million for the three-year period ended December 31, 2024, with an accumulated deficit of approximately $2.0 billion[173]. - The company has approximately $100.3 million of indebtedness as of December 31, 2024, which may limit cash flow available for business investments[179]. - Future capital requirements are expected to be substantial, and the company may need to raise additional funds to continue planned operations[167]. - The company expects to continue incurring significant expenses for the research and development of pilavapadin, LX9851, and sotagliflozin[175]. - The company's operating results have fluctuated in the past and are likely to continue to do so, making period-to-period comparisons unreliable[176]. - The company may not have sufficient capital to support Phase 3 development of pilavapadin in neuropathic pain, which could require additional financing[171]. Collaborations and Licensing Agreements - The company entered into an exclusive license agreement with Viatris Inc. for the development and commercialization of sotagliflozin, receiving a $25 million upfront payment and potential milestone payments totaling up to $197 million[38]. - Viatris is responsible for all regulatory and commercialization activities for sotagliflozin in the licensed territory, including conducting additional clinical trials[39]. - The company established a drug discovery alliance with Bristol-Myers Squibb, receiving $86 million in upfront payments and research funding, with potential milestone payments of up to $76 million for each drug developed[40][41]. - The company has agreed to pay Bristol-Myers Squibb up to $34.5 million in clinical and regulatory milestones for the first indication of pilavapadin and up to $40 million in commercial milestones[42]. - The company collaborates with various pharmaceutical and biotechnology companies, receiving fees for generating knockout mice and providing phenotypic data, with potential milestone or royalty payments[43]. Regulatory Environment and Compliance - The FDA requires a substantial user fee for the submission of a New Drug Application (NDA), which must include comprehensive data on chemistry, manufacturing, and clinical efficacy[61]. - FDA approval processes can take many years, with significant variability based on the drug's complexity and the disease it targets, potentially delaying market entry[63]. - The FDA may grant conditional marketing authorizations for products with incomplete clinical datasets if the risk-benefit balance is positive[74]. - Orphan drug designation in the U.S. provides tax credits of up to 25% for qualified clinical trial expenses and can offer seven years of market exclusivity for rare diseases affecting fewer than 200,000 people[68]. - The FDA's Fast Track and priority review programs aim to expedite the approval process for drugs addressing serious conditions, with priority review reducing the initial review time to six months[69]. - The 21st Century Cures Act enhances FDA processes for drug approval, including the use of real-world evidence and complex adaptive trial designs[70][76]. - Compliance with FDA regulations is mandatory for drug manufacturers, including adherence to current Good Manufacturing Practices (cGMP) and regular inspections[62][65]. - The FDA restricts marketing and promotion of drugs to approved uses only, with potential penalties for non-compliance[66][67]. - Federal and state healthcare laws impose strict compliance requirements on the company, with significant penalties for violations[79]. - The company is subject to various federal and state laws regarding the collection and use of personal information, which may increase operational costs and create liability risks[80]. - The Physician Payments Sunshine Act requires manufacturers to report certain payments to physicians, potentially impacting sales and marketing activities due to compliance burdens[81]. - For products covered by Medicaid, the company must offer substantial rebates and discounts, which complicates pricing strategies and compliance efforts[82]. - The Affordable Care Act (ACA) has significantly impacted the healthcare industry, including increased Medicaid rebates and new pricing methodologies for biopharmaceutical products[85]. - The Inflation Reduction Act of 2022 introduces penalties for drug price increases above inflation rates and government price-setting for certain Medicare drugs starting in 2026[87]. - The company’s compliance with environmental and worker safety regulations may require significant capital expenditures in the future[93]. Competition and Market Dynamics - The company faces significant competition in the biotechnology and pharmaceutical industries, with competitors having greater resources and capabilities[47]. - The principal competition for pilavapadin includes duloxetine and pregabalin, while LX9851 competes with approved weight loss drugs[50][51]. - The company expects competition for sotagliflozin in treating hypertrophic cardiomyopathy from generic beta blockers and cardiac myosin inhibitors[53]. - Third-party payers are increasingly limiting coverage and reimbursement for new drugs, creating uncertainty in pricing and demand[154]. - The COVID-19 pandemic has disrupted business operations and clinical trials, potentially impacting future commercialization efforts[158]. - The emergence of new COVID-19 variants could further disrupt recruitment for clinical trials and overall business operations[159]. - The company faces intense competition from other pharmaceutical and biotechnology firms, which may hinder the commercialization of its drug candidates[156]. Intellectual Property and Trade Secrets - The company faces challenges in protecting its intellectual property, which could adversely affect its competitive position in the market[192]. - The patent positions of biotechnology and pharmaceutical companies, including the company, are generally uncertain and may not provide sufficient protection against competitors[193]. - The company may incur substantial costs in defending its patents and intellectual property rights, with uncertain outcomes that could negatively impact its business[194]. - The company is at risk of being blocked from using its drug candidates if third-party patents are issued, which could limit its ability to commercialize products[195]. - The company relies on trade secret protection for proprietary information, but measures taken may not provide adequate protection against competitors[198]. Workforce and Management - As of February 28, 2025, the company employed 103 persons, with 19 holding M.D. or Ph.D. degrees and 33 holding other advanced degrees[108]. - The company has experienced substantial growth in employee numbers, which may place significant demands on its management and operational resources[210]. - The loss of key personnel could impair the company's ability to operate and expand its operations effectively[212]. - The company may face challenges in recruiting and retaining qualified personnel, which is critical for advancing its research and development efforts[213]. - The company’s executive team includes experienced leaders from major pharmaceutical firms, enhancing its strategic capabilities[97][98][99].